Mixtard 50 Penfill (Insulin Human)

Insulin human, the active ingredient in Mixtard 50 Penfill, is an insulin presented as a 100 IU/mL prefilled pen for subcutaneous use. It replaces deficient endogenous insulin, lowering blood glucose, and is indicated for the management of type 1 and type 2 diabetes mellitus in adults and children.

GNH USA supplies Mixtard 50 Penfill as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and providing regulatory‑approved products to global healthcare providers through reliable logistics.

Mixtard 50 Penfill, a human insulin formulation, acts within the insulin‑dependent pathway to control blood glucose in diabetes.

Type 1 diabetes mellitus: provides basal and prandial insulin to achieve target glycemic control. Type 2 diabetes mellitus: improves insulin deficiency and resistance, helping patients reach individualized glucose goals. Blood glucose management: reduces hyperglycemia episodes and supports overall metabolic stability. Prevention of acute hyperglycemic crises: maintains stable glucose levels, reducing the risk of ketoacidosis and hyperosmolar states.

Insulin human may cause adverse reactions ranging from mild to severe.

Common Side Effects: - Hypoglycemia: low blood glucose episodes with symptoms such as sweating, tremor, or confusion. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: increase in body weight associated with improved glucose utilization.

Serious or Rare Side Effects: - Severe hypoglycemia: profound low glucose that can lead to seizures or loss of consciousness. - Allergic reactions: rash, urticaria, or anaphylaxis requiring immediate medical attention. - Insulin antibodies: formation of antibodies that may alter insulin action.

When using Mixtard 50 Penfill, several precautions should be observed to ensure safe and effective therapy.

- Blood glucose monitoring: check levels regularly to adjust dose as needed. - Dose adjustment during illness: reduce or increase insulin based on carbohydrate intake and activity. - Caution in renal or hepatic impairment: may require lower doses and closer monitoring. - Avoid use in hypoglycemia: do not administer if blood glucose is already low. - Pregnancy and lactation: considered safe (Category B) but use under medical supervision. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Insulin human can interact with other medicines, altering its glucose‑lowering effect or increasing the risk of adverse events.

Major Interactions (Avoid): - Beta‑blockers: may mask hypoglycemia symptoms, requiring careful monitoring. - Sulfonylureas and meglitinides: additive glucose‑lowering effect can cause severe hypoglycemia. - ACE inhibitors and ARBs: may potentiate insulin’s effect, increasing hypoglycemia risk.

Moderate Interactions (Monitor Closely): - Corticosteroids: raise blood glucose, possibly necessitating higher insulin doses. - Thiazide diuretics: can increase blood glucose modestly. - Oral contraceptives: may slightly reduce insulin sensitivity.